

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventors: Elizabeth Mannick *et al.* Group: 1634
Filing Date: June 27, 2005 Examiner: Sitton, J.S.
Serial Number: 10/540,951
Title: "Target Genes for Inflammatory Bowel Diseases"
Attorney File: Mannick 04M11-US

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

AMENDMENT AND RESPONSE TO RESTRICTION REQUIREMENT

In response to the October 3, 2007 Restriction Requirement, Applicants elect Group II (Claims 1-14), drawn to methods involving detecting the presence or absence of a polymorphism in CSFIR with primers SEQ ID NOS. 3 and 4. The Office also entered an election of species requirement for the listing of compounds in Claim 14. Applicants elect the species of the use of mifepristone to treat a patient in which a polymorphism of a CSFIR gene associated with a genetic predisposition for inflammatory bowel disease has been detected. Claims 7-14 read on the elected species.

Applicants are paying a fee of \$230 by credit card, through Private PAIR, as a small entity, to extend the date for response from November 3, 2007 to January 3, 2008 (37 C.F.R. § 1.136(a)(3)). If this amount is incorrect, please refer to the Deposit Account Authorization previously filed with this application. If any additional extension of time is required, please consider this paper a petition for the total extension of time required.

Please amend the claims as follows:

Amendments to the Claims are reflected in the listing of claims which begins on page 2.

Remarks begin on page 5.